Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature
Utter K, Goldman C, Weiss SA, Shapiro RL, Berman RS, Wilson MA, Pavlick AC, Osman I. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. Oncology 2017, 93: 249-258. PMID: 28746931, PMCID: PMC5617794, DOI: 10.1159/000478050.Peer-Reviewed Original ResearchConceptsMUP patientsProspective melanoma databaseSystemic therapyUnknown primaryMetastatic melanomaClinical trialsSingle-institution studyMKP patientsTreatment guidelinesPoor outcomeMelanoma databaseWorse outcomesTreatment outcomesPatientsBetter outcomesTherapyPatient dataMelanomaGoogle ScholarUnique populationSurvival dataOutcomesLimited dataImmunotherapyTrialsTargeting EZH2 in acral lentiginous melanoma (ALM).
Izsak A, Giles K, Lui K, Weiss S, Moran U, Vega-Saenz de Miera E, Stein J, Lee A, Darvishian F, Shapiro R, Berman R, Pavlick A, Wilson M, Osman I. Targeting EZH2 in acral lentiginous melanoma (ALM). Journal Of Clinical Oncology 2017, 35: 9534-9534. DOI: 10.1200/jco.2017.35.15_suppl.9534.Peer-Reviewed Original ResearchAcral lentiginous melanomaCM cell linesCutaneous melanomaALM casesCell linesMetastatic progressionEZH2 expressionMetastatic acral lentiginous melanomaEZH2 inhibitionEZH2 inhibitorsEffects of GSK126Mean IHC scoreColony formationEZH2 protein expressionClinicopathological dataPrimary tumorLentiginous melanomaMetastatic tumorsClinical trialsHistone methyltransferase EZH2Treatment outcomesIHC scoreLow dosesTherapeutic potentialTumors